ACA stabilization package would boost coverage, lower premiums on individuals

A pair of bills to fund the Affordable Care Act’s cost-sharing reduction (CSR) subsidies and create a new reinsurance program would lower monthly premiums for exchange plans by 20 to 40 percent and boost enrollment by 3.2 million people. Conservative groups, however, call the legislation a “bailout” for insurance companies.

The analysis came from Oliver Wyman and was touted by the Republicans sponsors of bills, Sens. Lamar Alexander, R-Tennessee, and Susan Collins, R-Maine, saying it “further demonstrates that our bipartisan proposals will help drive down premiums in the individual market and make health insurance more affordable for millions of Americans.”

The Washington Post reports the stabilization bills—which were first promised to be considered late in 2017—remain in political limbo. Democrats don’t like Republican efforts to chip away at the ACA through piecemeal legislation and regulatory action, while Republicans are divided over how to deal with the ACA since full repeal has been taken off the table.

Demonstrating the intraparty split, conservative groups like Heritage Action and FreedomWorks have written to congressional leaders saying the extra money would “do nothing to address the real reasons premiums and deductibles are rising,” which they blame on the ACA’s regulations and subsidies.

“The same insurers who are lobbying for bailout money this year will be back again when funding expires, threatening to withdraw from the exchanges or raise premiums if bailouts aren’t extended,” they wrote.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.